My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

39 40 Next >

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

June 26, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗

June 20, 2024

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

Via Benzinga

Topics Lawsuit

Is It Too Late to Buy Novavax Stock? ↗

June 14, 2024

Shares of the vaccine maker are trading up 230% this year.

Via The Motley Fool

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗

June 13, 2024

The companies are closing in on the finish line for two new COPD treatments.

Via Investor's Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club ↗

June 12, 2024

Enthusiasm is growing for a looming approval in COPD treatment.

Via Investor's Business Daily

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge ↗

June 12, 2024

The integration of AI and healthcare is well underway.

Via The Motley Fool

Topics Artificial Intelligence

Bull Market and Beyond: 3 Stocks Just Waiting to Soar ↗

June 11, 2024

These pharma and biotech players could become long-term winners.

Via The Motley Fool

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗

June 10, 2024

If approved, this would be the first combination vaccine based on mRNA technology to hit the market.

Via Investor's Business Daily

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗

June 07, 2024

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

Via InvestorPlace

The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash ↗

June 07, 2024

Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty.

Via InvestorPlace

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients ↗

June 04, 2024

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

Via Benzinga

3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth ↗

June 03, 2024

Explore three reliable dividend growth stocks for June 2024 to expand your investment profits for the second half of the year.

Via InvestorPlace

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet ↗

June 01, 2024

These are the overpriced growth stocks to sell and buy after these names corrected by 20% to 30% in the coming quarters.

Via InvestorPlace

FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗

May 31, 2024

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from...

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

May 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

May 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3 ↗

May 29, 2024

For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conference that combines elements of business, pop culture

Via Benzinga

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗

May 28, 2024

Via Benzinga

Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit ↗

May 24, 2024

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.

Via Benzinga

Topics Lawsuit

Why Vaccine Stocks Rallied This Week ↗

May 24, 2024

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

Via The Motley Fool

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom ↗

May 23, 2024

These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.

Via InvestorPlace

First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential ↗

May 22, 2024

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

Via Benzinga

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗

May 22, 2024

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...

Via Benzinga

3 Biotech Stocks to Buy Now: May 2024 ↗

May 22, 2024

As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.

Via InvestorPlace

3 Things You Need to Know If You Buy Novavax Today ↗

May 22, 2024

The vaccine maker's recovery story is looking brighter.

Via The Motley Fool

ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development ↗

May 21, 2024

Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma...

Via Benzinga

Topics Artificial Intelligence

Roaring Kitty’s Rally Cry: 3 Meme Stocks to Pounce On Now ↗

May 20, 2024

Jump into action with NVAX, HOOD and WKHS as top meme stocks to buy, offering the chance to capitalize on short squeezes and momentum.

Via InvestorPlace

This Stock Just More Than Doubled in 1 Day: Is It a Buy? ↗

May 19, 2024

The biotech still hasn't lost momentum.

Via The Motley Fool

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.